Novartis' Reclast reduces risk of repeat hip fractures in elderly

09/17/2007 | USA Today

The osteoporosis drug Reclast reduces the risk of additional hip fractures in older people, a Novartis-funded study found. In observing 2,127 men and women who had broken their hips within three months prior to the study and took calcium and vitamin D supplements, researchers found that intravenous administration of Reclast once a year significantly lowered the chances of patients suffering repeat fractures, which are associated with an increased risk of death in older adults.

View Full Article in:

USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX